You're losing revenue.

Is the sun setting on research sites?

Yesterday, your pharma customers came to you for patients.
Today, you're competing with CVS pharmacies.
leadership

We’re post COVID and the digital-health and decentralized clinical trials train has left the station. Are you on it?

Before COVIID-19,  pharma companies went to research sites to find patients. Decentralized trials technologies now enable pharma to conduct trials from pharmacies and community-based clinics. Is DCT a threat or an opportunity for you?

Healthcare Providers are no longer the primary source of clinical trial data

Patient-generated data is rapidly outstripping EMR systems in terms of volume, velocity and value. The wearable healthcare technology market is surging, and its maturation will put more devices in the hands of consumers and businesses. According to Business Insider Intelligence research, the total installed base of fitness tracker and health-based wearables in the US will grow at an annualized rate of 10% to surpass 120 million by 2023.

As a result,  EMR is no longer the primary source document in clinical trials.  With its limited connectivity and sharing capabilities EMR systems are now an extremely small part of the overall picture of a person’s health today. These records are primarily kept and utilized for the purposes of insurance reimbursement.

Digital health/digital therapeutic companies that need RWD in order to design, implement and validate their product now go directly to the patient. This includes pure-play digital health companies as well as drug and device companies that are increasingly using RWD (real-world-data) for product development and monitoring. Use of digital therapeutics in clinical R&D include interventional drug and devices for chronic disease management (COPD, Stroke recovery, CHF), pain and gastro.

Healthcare IoT is 10X bigger than hospital EMR and growing 4X faster each year

Mobile enables more procedures to occur away from hospital – threatening site revenue streams.

The shift of clinical-trial activities closer to patients has been enabled by a constellation of evolving technologies and services. Tools such as electronic consent, tele-healthcare, remote patient monitoring, and electronic clinical-outcome assessments (eCOAs) allow investigators to maintain links to trial participants without in-person visits. Mobile and home healthcare, as well as alternative-care locations, enable more procedures to occur away from research sites. 

Create a new business opportunity for your site.

Download the 
white paper 

Scroll to Top